Effects of Acute or Prolonged Administration of Cabergoline on Parkinsonism Induced by MPTP in Common Marmosets-Reference-Cited by-同舟云学术

Effects of Acute or Prolonged Administration of Cabergoline on Parkinsonism Induced by MPTP in Common Marmosets

Published:1998-03 Issue:3 Volume:59 Page:717-721
ISSN:0091-3057
Container-title:Pharmacology Biochemistry and Behavior
language:en
Short-container-title:Pharmacology Biochemistry and Behavior

Author:

Nomoto M,Kita S,Iwata S.-I,Kaseda S,Fukuda T

Publisher

Elsevier BV

Subject

Behavioral Neuroscience,Biological Psychiatry,Clinical Biochemistry,Pharmacology,Toxicology,Biochemistry

Reference22 articles.

1. Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.50, and 1.5 milligrams) in healthy male volunteers;Andreotti;J. Clin. Endocrinol. Metab.,1995

2. In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine;Benedetti;Eur. J. Pharmacol.,1990

3. The role of bromocriptine in the treatment of parkinsonism;Fahn;Neurology,1979

4. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients;Ferrari;J. Clin. Endocrinol. Metab.,1986

5. Dopamine (3-hydroxytryptamine) and brain function;Hornykiewicz;Pharmacol. Rev.,1966

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations;Behavioural Pharmacology;2020-02

2. Physiological and Functional Basis of Dopamine Receptors and Their Role in Neurogenesis: Possible Implication for Parkinson’s disease;Journal of Experimental Neuroscience;2018-01

3. Neurotoxin 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Induced Animal Models of Parkinson’s Disease;Animal Models for the Study of Human Disease;2017

4. Refinement of the MPTP model for Parkinson’s disease in the marmoset;Drug Discovery Today: Disease Models;2017

5. Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage;Neuroscience;2016-01